This category page covers biotechnology and pharmaceutical companies developing Nrf2 activators, Keap1 inhibitors, antioxidant response element (ARE) modulators, and oxidative stress reduction therapies for Alzheimer's disease. The Nrf2-Keap1 pathway is the primary cellular defense mechanism against oxidative stress, a core pathological hallmark of Alzheimer's disease. Activation of Nrf2 leads to upregulation of antioxidant genes, enhancement of mitochondrial function, suppression of neuroinflammation, and protection against amyloid-beta and tau toxicity.
Companies targeting this pathway aim to restore redox homeostasis in the AD brain, addressing a fundamental upstream driver of neurodegeneration rather than downstream amyloid or tau pathology alone.
| Approach |
Description |
Companies |
| Direct Nrf2 Activators |
Bind KEAP1 cysteine residues to release Nrf2 |
Reata/Alnylam, Biogen, Nacuity |
| Keap1 Inhibitors |
Disrupt Keap1-Nrf2 binding to free Nrf2 |
Evotec, academia spinouts |
| ARE Modulators |
Modulate antioxidant response element transcription |
Various research-stage |
| Oxidative Stress Reducers |
Scavenge ROS, support glutathione pathways |
Cyclo Therapeutics, Pfizer |
| Mitochondrial Nrf2 |
Target Nrf2 to improve mitochondrial function |
Indus Therapeutics |
| Combination Approaches |
Nrf2 + anti-inflammatory or metabolic targets |
Oryzon Genomics, Alector |
- Focus: Nrf2 activation for AD and other neurodegenerative conditions
- Lead Candidate: Bardoxolone methyl (omaveloxolone variant)
- Mechanism: Covalently binds KEAP1 cysteine residues, releasing Nrf2 to translocate to the nucleus and activate ARE-driven gene expression
- Indication: Alzheimer's disease
- Stage: Phase 2
- Notes: Acquired by Alnylam in 2023. Bardoxolone methyl derivative (omaveloxolone) approved for Friedreich's ataxia. AD program leverages same Nrf2 activation mechanism with optimized CNS penetration strategy
- Key Targets: HO-1 (heme oxygenase-1), NQO1, GCL (glutamate-cysteine ligase), GSTA2
- Focus: Repurposing approved Nrf2 activators for neurodegeneration
- Lead Candidate: Dimethyl fumarate (Tecfidera)
- Mechanism: Nrf2 activator through KEAP1 modification; also has immunomodulatory effects through HCA2 receptor
- Indication: Alzheimer's disease, ALS
- Stage: Phase 3 (ALS), Phase 2 (AD)
- Notes: Already approved for multiple sclerosis. DIMSUM trial investigated dimethyl fumarate in early AD. Multiple mechanisms beyond Nrf2 including neuroprotection via HCA2 and modulation of gut immune axis
- Clinical Trials: DIMSUM (dimethyl fumarate for AD), Fumarate extension studies
Biogen
- Focus: Nrf2 activator for retinitis pigmentosa and neurodegenerative diseases
- Lead Candidate: NPI-001
- Mechanism: Nrf2 activator with potential for CNS and retinal applications; targets oxidative stress through ARE upregulation
- Indication: Alzheimer's disease (preclinical), retinitis pigmentosa (Phase 2)
- Stage: Phase 2 (RP), preclinical (AD)
- Notes: Australian biotech with Nrf2 platform. Strong scientific basis for AD applications given role of oxidative stress in neurodegeneration
- Focus: Drug discovery partnerships and Keap1/Nrf2 modulator development
- Mechanism: High-throughput screening for Keap1 inhibitors; partnered programs with pharma
- Indication: Alzheimer's disease, metabolic diseases
- Stage: Research/collaborative programs
- Notes: Evotec's multi-target CNS platform includes Nrf2 pathway modulators through academic and pharma partnerships. EVT-501 program and related Nrf2 activators under development through drug discovery collaborations
- Partnerships: Works with major pharma on CNS programs targeting oxidative stress pathways
Multiple academic groups have spun out companies targeting Keap1-Nrf2 for neurodegeneration:
| Company |
Institution Origin |
Program Stage |
| Keapstone Therapeutics |
University of Edinburgh |
Preclinical |
| Nrf2 Therapeutics Inc. |
Scripps/UC Irvine |
Preclinical |
| Orexo |
Swedish academic consortium |
Phase 1 |
- Focus: Oxidative stress reduction via wearable drug-device combination
- Lead Candidate: Medical device platform for chronic oxidative stress management
- Mechanism: Transcranial delivery of Nrf2-activating compounds; targets brain oxidative stress reduction
- Indication: Alzheimer's disease
- Stage: Early clinical development
- Notes: Novel drug-device approach combining Nrf2 activation with non-invasive brain delivery. Addresses the CNS penetration challenge that limits most Nrf2 activator therapeutics
- Focus: Mitochondrial function and Nrf2 pathway targeting
- Lead Program: Mitochondrial-targeted Nrf2 modulators
- Mechanism: Mitochondrial-specific Nrf2 activation; protects neuronal mitochondria from oxidative damage
- Indication: Alzheimer's disease
- Stage: Preclinical
- Notes: Platform focused on targeting Nrf2 specifically to mitochondria. Addresses the energy metabolism deficit observed in AD brains
- Focus: Broad CNS portfolio including oxidative stress approaches
- Programs: Multiple Nrf2-related discovery programs through internal pipeline and partnerships
- Mechanism: Direct Nrf2 activators and upstream modulators of oxidative stress pathways
- Indication: Alzheimer's disease
- Stage: Discovery to Phase 1
- Notes: Significant investment in oxidative stress and neuroprotection approaches for AD. Pfizer Ventures has backed several Nrf2-focused biotech companies
Pfizer
- Focus: Epigenetic modulation with Nrf2 pathway implications
- Lead Candidate: Iadademstat (ORY-2001) — LSD1 inhibitor with potential Nrf2 cross-talk
- Mechanism: LSD1 (KDM1A) inhibition modulates gene expression; Nrf2 pathway effects through epigenetic regulation of antioxidant genes
- Indication: Alzheimer's disease, Parkinson's disease
- Stage: Phase 2 (AD), Phase 1 (PD)
- Notes: Spanish biotech with dual epigenetic and oxidative stress focus. ORY-2001 targets CNS diseases through modulation of neuroinflammatory and oxidative stress gene networks. LSD1 inhibition upregulates Nrf2 pathway genes as secondary mechanism
- Key Trials: ROSA-AD trial (iadademstat in AD)
- Focus: Immune dysfunction and neurodegeneration including oxidative stress pathways
- Programs: Multiple programs targeting neuroinflammation and neuronal health
- Mechanism: Immune-based approaches with oxidative stress cross-talk; Nrf2 pathway interactions through immune-neural cross-regulation
- Indication: Alzheimer's disease, Parkinson's disease
- Stage: Phase 2/3
- Notes: While primarily focused on TREM2 and immune therapies, Alector's programs have implications for oxidative stress resolution in neurodegeneration. Their broad neuroimmunology platform intersects with Nrf2 pathway biology
Alector
¶ Natural Product and Dietary Supplement Companies
Multiple companies and academic groups are developing sulforaphane (broccoli-derived Nrf2 activator) for AD:
| Developer |
Product |
Stage |
Notes |
| Evgen Pharma |
SFX-01 (stabilized sulforaphane) |
Phase 2 |
AD trials in UK; oral formulation |
| Various academic |
Broccoli extract / sulforaphane |
Phase 2 |
Multiple investigator-initiated trials |
| Nutritex |
Nrf2-activating botanical |
Preclinical |
Multi-target antioxidant |
| Company |
Drug/Program |
Mechanism |
Phase |
Indication |
| Alnylam (Reata) |
Bardoxolone methyl |
Nrf2 direct activator |
Phase 2 |
AD |
| Biogen |
Dimethyl fumarate |
Nrf2 activator |
Phase 3 |
ALS, Phase 2 AD |
| Oryzon Genomics |
Iadademstat |
LSD1/Nrf2 cross-talk |
Phase 2 |
AD |
| Nacuity |
NPI-001 |
Nrf2 activator |
Preclinical |
AD |
| Evotec |
Keap1 inhibitors |
Keap1-Nrf2 disruptors |
Discovery |
AD |
| Indus Therapeutics |
Mito-Nrf2 modulators |
Mitochondrial Nrf2 |
Preclinical |
AD |
| Cyclo Therapeutics |
Device+Nrf2 |
Oxidative stress reduction |
Early clinical |
AD |
| Evgen Pharma |
SFX-01 |
Sulforaphane |
Phase 2 |
AD |
| Alector |
Various |
Immune/Nrf2 |
Phase 2/3 |
AD |
The Nrf2-Keap1 pathway operates as follows in Alzheimer's disease:
- Under normal conditions: Nrf2 is bound by Keap1 in the cytoplasm and targeted for ubiquitin-mediated degradation
- Oxidative stress: Electrophilic compounds (or ROS) oxidize Keap1 cysteine residues, causing conformational change
- Release: Nrf2 is released from Keap1 inhibition and translocates to the nucleus
- Gene activation: Nrf2 binds ARE sequences in DNA, upregulating:
- Antioxidant enzymes: HO-1, SOD1, SOD2, CAT, GPX
- Detoxification: NQO1, GST, GCL (glutathione synthesis)
- Mitochondrial genes: TFAM, PGC-1α, respiratory chain components
- Chaperones: Hsp70,.sql Hsp90
- Proteasome subunits: PSMB5, PSMD4
| AD Feature |
Nrf2 Relationship |
| Amyloid-beta toxicity |
Nrf2 activation reduces Aβ-induced ROS and protects neurons |
| Tau hyperphosphorylation |
Nrf2 suppresses kinase activation through redox regulation |
| Neuroinflammation |
Nrf2 inhibits NF-κB pathway, reducing microglial activation |
| Mitochondrial dysfunction |
Nrf2 upregulates mitochondrial biogenesis genes |
| Synaptic loss |
Nrf2 protects synaptic proteins from oxidative damage |
| Cognitive decline |
Nrf2 activation correlates with preserved cognition in models |
The major barrier for Nrf2-targeted AD therapies is limited brain penetration. Most electrophilic Nrf2 activators (bardoxolone, sulforaphane) have suboptimal CNS exposure. Companies are addressing this through:
- Pro-drug strategies: Convert inactive pro-drugs to active Nrf2 activators in the brain
- Nanoparticle delivery: Encapsulate Nrf2 activators for brain-targeted delivery
- Device-assisted delivery: Cyclo Therapeutics' approach of transcranial delivery
- Intrathecal administration: Direct CNS dosing for maximum exposure
- Blood-brain barrier (BBB) shuttles: Engineering Nrf2 activators with BBB-targeting moieties